ClinicalTrials.gg

Program

aflutinib

Also written as “Furmonertinib”, “Alflutinib” and “ASK120067”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Neoplasm Metastasis · Breast Neoplasms, led by 6 companies.

Furthest: phase 3, since Apr 12, 202121 company-led studies, 11 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Allist Pharmaceuticals114 open or runningphase 3since Apr 12, 2021Nov 21, 2016Dec 2026phase 3 · NCT04853342
Beijing Aosaikang Pharmaceutical41 open or runningphase 3since Oct 12, 2019Apr 10, 2018none ahead
ArriVent BioPharma33 open or runningphase 3since Oct 31, 2022Apr 6, 2022Feb 2029phase 3 · NCT07185997
Abbisko Cayman11 open or runningphase 2since Oct 30, 2024Oct 30, 2024Dec 30, 2027phase 2 · NCT06668103
Alphamab Oncology11 open or runningphase 1since Mar 5, 2025Mar 5, 2025Jun 30, 2028phase 1 · NCT06868732
MediLink Therapeutics (Suzhou)11 open or runningphase 2since Sep 3, 2025Sep 3, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 7 studies since Nov 21, 2016.

  1. Apr 20, 2020Phase 1 study in Carcinoma, Non-Small-Cell LungBeijing Aosaikang Pharmaceutical · NCT04360915 · 24 enrolled · China
  2. Apr 12, 2021Phase 1 study in NSCLCAllist Pharmaceuticals · NCT04858958 · 90 enrolled · China
  3. Apr 12, 2021Phase 3 study in Carcinoma, Non-Small-Cell LungAllist Pharmaceuticals · NCT04853342 · 318 planned · China
  4. Jul 5, 2021Phase 1 study in NSCLCAllist Pharmaceuticals · NCT04958967 · China
  5. Apr 6, 2022ArriVent BioPharma's first study: phase 1 study in Carcinoma, Non-Small-Cell LungNew to ArriVent BioPharmaArriVent BioPharma · NCT05364073 · 160 enrolled · United States, Australia, Canada and more
  6. Jul 14, 2022Phase 2 study in NSCLCAllist Pharmaceuticals · NCT05466149 · 100 enrolled · China
  7. Oct 31, 2022Phase 3 study in Carcinoma, Non-Small-Cell LungArriVent BioPharma · NCT05607550 · 398 enrolled · United States, Australia, Brazil and more
  8. Nov 11, 2022Phase 1 study in Carcinoma, Non-Small-Cell LungBeijing Aosaikang Pharmaceutical · NCT05631678 · 48 enrolled · China
  9. Oct 30, 2024Abbisko Cayman's first study: phase 2 study in Non-Small Cell Lung Cancer With EGFR MutationNew to Abbisko CaymanAbbisko Cayman · NCT06668103 · 54 planned · China
  10. Mar 5, 2025Alphamab Oncology's first study: phase 1 study in Advanced Non-small Cell Lung CancerNew to Alphamab OncologyAlphamab Oncology · NCT06868732 · 288 planned · China
  11. Apr 9, 2025Phase 3 study in NSCLC Patients With Brain MetastasisAllist Pharmaceuticals · NCT06970639 · 380 planned · China
  12. May 20, 2025Phase 3 study in NSCLCAllist Pharmaceuticals · NCT07010419 · 338 planned · China
  13. Aug 15, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungArriVent BioPharma · NCT07185997 · 480 planned · United States, Australia, Canada and more
  14. Sep 3, 2025MediLink Therapeutics (Suzhou)'s first study: phase 2 study in Breast NeoplasmsNew to MediLink Therapeutics (Suzhou)MediLink Therapeutics (Suzhou) · NCT07169994 · 414 planned · China

Ahead

  1. Dec 2026Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungAllist Pharmaceuticals · NCT04853342
  2. Dec 30, 2027Primary completion: phase 2 study in Non-Small Cell Lung Cancer With EGFR MutationAbbisko Cayman · NCT06668103
  3. Jun 30, 2028Primary completion: phase 1 study in Advanced Non-small Cell Lung CancerAlphamab Oncology · NCT06868732
  4. Oct 31, 2028Primary completion: phase 3 study in NSCLCAllist Pharmaceuticals · NCT07010419

TargetBeta

EGFR →read by rule
“The mesylate salt form of alflutinib, an orally available selective inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, ”NCIt, by rule

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
pimurutamabFosun Pharmaphase 317
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
andamertinibruleavistone-biotechnology-co-ltdphase 310
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
zipalertinibruleOtsukaphase 34

Studies

All 21 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07169994Breast Neoplasms · China2RecruitingMediLink Therapeutics (Suzhou)Sep 1, 2026414
NCT07185997Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more3RecruitingArriVent BioPharmaFeb 2029480
NCT07010419NSCLC · China3RecruitingAllist PharmaceuticalsOct 31, 2028338
NCT06970639NSCLC Patients With Brain Metastasis · China3RecruitingAllist PharmaceuticalsMar 2029380
NCT06868732Advanced Non-small Cell Lung Cancer · China1RecruitingAlphamab OncologyJun 30, 2028288
NCT06668103Non-Small Cell Lung Cancer With EGFR Mutation · China2RecruitingAbbisko CaymanDec 30, 202754
NCT05631678Carcinoma, Non-Small-Cell Lung · China1CompletedBeijing Aosaikang PharmaceuticalAug 3, 202248
NCT05607550Carcinoma, Non-Small-Cell Lung · United States, Australia, Brazil and more3Active, not recruitingArriVent BioPharmaOct 6, 2026398
NCT05466149NSCLC · China2Active, not recruitingAllist PharmaceuticalsJun 27, 2025100
NCT05364073Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more1Active, not recruitingArriVent BioPharmaJun 3, 2025160
NCT04958967NSCLC · China1WithdrawnAllist PharmaceuticalsMay 1, 20220
NCT04858958NSCLC · China1CompletedAllist PharmaceuticalsDec 5, 202490
NCT04853342Carcinoma, Non-Small-Cell Lung · China3RecruitingAllist PharmaceuticalsDec 2026318
NCT04360915Carcinoma, Non-Small-Cell Lung · China1CompletedBeijing Aosaikang PharmaceuticalDec 30, 201924
NCT04143607Carcinoma, Non-Small-Cell Lung · China3Active, not recruitingBeijing Aosaikang PharmaceuticalMar 31, 2024337
NCT03941340Healthy Male Volunteers · China1CompletedAllist PharmaceuticalsSep 6, 20196
NCT03926182Healthy Male Volunteers · China1CompletedAllist PharmaceuticalsApr 3, 201916
NCT03502850Carcinoma, Non-Small-Cell Lung · China2UNKNOWNBeijing Aosaikang PharmaceuticalJan 2021507
NCT03452592Advanced NSCLC Patients With T790M · China2TerminatedAllist PharmaceuticalsApr 21, 2021220
NCT03127449Advanced NSCLC · China–TerminatedAllist PharmaceuticalsMay 12, 2021116
NCT02973763NSCLC1TerminatedAllist PharmaceuticalsFeb 4, 202114

How it is read

Names in the registry

  • “Furmonertinib”, 6 entries
  • “Alflutinib”, 3 entries
  • “ASK120067”, 3 entries
  • “Firmonertinib”, 2 entries
  • “Furmonertinib 160mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.